Video

Dr. Vaishampayan highlights new options in second-line urothelial cancer

Ulka Nitin Vaishampayan, MBBS, director, Phase I Program, Rogel Cancer Center, Michigan Medicine, professor of internal medicine, University of Michigan, discusses new options available for the second-line treatment of urothelial cancer, including the antibody-drug conjugates enfortumab vedotin (Padcev) and sacituzumab govitecan (Trodelvy).

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
4 experts in this video
4 experts in this video
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
4 experts in this video
4 experts in this video
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Related Content
© 2025 MJH Life Sciences

All rights reserved.